FORM 4

### **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Washington, D.C. 20049

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addr	ess of Reporting Pe	erson <sup>*</sup>	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]		ationship of Reporting Pe call applicable) Director Officer (give title	rson(s) to Issuer  10% Owner  Other (specify	
INCORPORAT	VO VERTEX PHARMACEUTICALS ICORPORATED O NORTHERN AVENUE  reet) OSTON MA 02210		3. Date of Earliest Transaction (Month/Day/Year) 02/05/2020		below) below) EVP, Global Research and CSO		
50 NORTHER  (Street)  BOSTON  (City)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	ividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person		

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership 7. Nature Transaction Form: Direct of Indirect Execution Date Securities Beneficially (Month/Day/Year) if anv Code (Instr. (D) or Indirect **Beneficial** (Month/Day/Year) 8) Owned Following Ownership (Instr. 4) (I) (Instr. 4) Reported (A) or (D) Transaction(s) ٧ Price Code Amount (Instr. 3 and 4) Common Stock 02/05/2020 18,204(1) \$0.00 49,757 Α A D Common Stock 02/05/2020 A 8,166(2) A \$0.00 57,923 D Common Stock 02/05/2020 A 12,387(3) A \$0.00 70,310 D 02/06/2020 M D \$187.53 71,613 D Common Stock 1.303 Common Stock 02/06/2020 M 1,223 D \$155.57 72,836 D S<sup>(4)</sup> Common Stock 02/06/2020 1,462 D \$238.74(5)(6) 71,374 D S<sup>(4)</sup> Common Stock 02/06/2020 630 D \$239.63(4)(7) 70,744 D S<sup>(4)</sup> \$240,82(6)(8) Common Stock 02/06/2020 280 D 70,464 D Common Stock 02/06/2020 S<sup>(4)</sup> 154 D \$242.47 70,310 D

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$187.53	02/06/2020		M			1,303	(9)	02/05/2029	Common Stock	1,303	\$0.00	15,642	D	
Stock Option (Right to Buy)	\$155.57	02/06/2020		М			1,223	(10)	02/05/2028	Common Stock	1,223	\$0.00	9,783	D	

### Explanation of Responses:

- $1. \ Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020.$
- 2. Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 02/24/2020.
- 3. Restricted stock unit award that vests in installments beginning on 02/10/2021.
- 4. Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
- $5. \ Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \ \$238.74 \ (range \ \$238.16 \ to \ \$239.14).$
- 6. Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 7. Open market sales reported on this line occurred at a weighted average price of \$239.63 (range \$239.22 to \$240.04).
- 8. Open market sales reported on this line occurred at a weighted average price of \$240.82 (range \$240.60 to \$241.04).
- 9. The option vests in 16 quarterly installments from 02/06/2019.
- 10. The option vests in 16 quarterly installments from 02/06/2018.

Remarks:

/s/ Omar White, Attorney-in-

Fact

\*\* Signature of Reporting Person

02/07/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.